drugset / Trial / NCT01220895
Alternate Donor Study of Pre-Emptive Cellular Therapy
Phase 2
Completed
52 enrolled
Cell Medica Ltd
Leukaemia Lymphoma Research · collabNational Health Service, Blood and Transplant · collabUniversity of Birmingham · collab
RandomizedParallel-groupOpen-labelPrevention
Summary
The purpose of this study is to evaluate the potential clinical benefit of pre-emptive cytomegalovirus (CMV)-specific adoptive cellular therapy following T cell depleted allogeneic hematopoietic stem cell transplantation (HSCT) for reducing recurrent CMV reactivation.
Timeline
- Start
- 2010-10
- Primary completion
- 2013-12
- Completion
- 2014-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CMV-specific T-cells | Cell therapy | — | — |
| Background | Foscarnet | Small molecule | 90 mg/kg | Intravenous |
| Background | Ganciclovir | Small molecule | 5 mg/kg | Intravenous |
| Background | Valganciclovir | Small molecule | 900 mg | Oral |